EUVIMEDEUVIMED entdecken
Crossref

Pattern of Failure in Patients with Biochemical Recurrence After PSMA Radioguided Surgery

Lilit Schweiger, Tobias Maurer, Ricarda Simon, Thomas Horn, Matthias Heck, Wolfgang A Weber, Matthias Eiber, Isabel Rauscher

Journal of Nuclear Medicine · 2025

DOI: 10.2967/jnumed.124.268151 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nuclear Medicine, 2025. Verfasst von Lilit Schweiger und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, School of Medicine, Technical University of Munich, Munich, Germany; lilit.schweiger@mri.tum.de. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Glutamate Carboxypeptidase II, Antigens, Surface. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 19 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prostate-specific membrane antigen (PSMA)-targeted radioguided surgery (RGS) is evolving as a new treatment modality for patients with early biochemical recurrence of prostate cancer and disease limited to locoregional lymph nodes on PSMA-ligand PET/CT. Nevertheless, the pattern of failure (locoregional vs. systemic) after PSMA RGS remains unknown. Therefore, the aim of this retrospective analysis was to evaluate the pattern of disease using PSMA-ligand PET in patients experiencing relapse after PSMA RGS.

Methods

We evaluated 100 patients with biochemical recurrence after previous PET-guided PSMA RGS who underwent PSMA-ligand PET (median prostate-specific antigen [PSA], 0.9 ng/mL; range, 0.2-14.2 ng/mL). All suspicious lesions for recurrent prostate cancer were grouped according to the molecular imaging TNM classification system. Detection rates and lesion localization were determined and stratified by PSA values and the International Society of Urological Pathology grade group. Further, lesion localization was compared before and after PSMA RGS.

Results

The median time between PSMA RGS and PSMA-ligand PET for relapse was 11.4 mo (range, 5.5-25.6 mo). In total, 91 of 100 (91%) patients showed PSMA-ligand-positive findings. PSMA PET detection rates were 82.6%, 92.6%, 91.3%, and 96.3% for PSA levels of 0.2-0.49, 0.5-0.99, 1-1.99, and at least 2 ng/mL, respectively. More than half of the patients (53%; 48/91) showed local recurrence or pelvic lymph node metastases only. Extrapelvic lymph node metastases, bone metastases, and visceral metastases were present in 22% (20/91), 16% (15/91), and 9% (8/91) of the patients, respectively. With increasing International Society of Urological Pathology grade group, the percentage of patients with bone and visceral metastases increased, whereas the number of patients with only locoregional disease decreased.

Conclusion

PSMA-ligand PET is a useful method to detect and localize recurrent disease in patients with biochemical failure after PSMA RGS, with more than half of the patients presenting with locoregional recurrence, offering the potential for a second local therapy (e.g., radiation therapy or repeated surgery).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsGlutamate Carboxypeptidase IIAntigens, SurfaceHumansMaleAgedRetrospective StudiesMiddle AgedSurgery, Computer-AssistedRecurrenceAged, 80 and overPositron Emission Tomography Computed TomographyNeoplasm Recurrence, LocalTreatment FailureProstate-Specific Antigen

Stichwörter der Autor:innen

biochemical recurrenceprostate cancerprostate‐specific membrane antigenradioguided surgery

Substanzen

Glutamate Carboxypeptidase IIAntigens, SurfaceFOLH1 protein, humanProstate-Specific Antigen

Autor:innen und Institutionen

  • Department of Nuclear Medicine, School of Medicine, Technical University of Munich, Munich, Germany; lilit.schweiger@mri.tum.de.
  • Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria.
  • Martini-Klinik and Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany; and.
  • Department of Urology, School of Medicine, Technical University of Munich, Munich, Germany.
  • Department of Nuclear Medicine, School of Medicine, Technical University of Munich, Munich, Germany.

Zitieren

APA

Schweiger, L., Maurer, T., Simon, R., Horn, T., Heck, M., Weber, W. A., Eiber, M., & Rauscher, I. (2025). Pattern of Failure in Patients with Biochemical Recurrence After PSMA Radioguided Surgery. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.124.268151

Vancouver

Schweiger L, Maurer T, Simon R, Horn T, Heck M, Weber WA, et al. Pattern of Failure in Patients with Biochemical Recurrence After PSMA Radioguided Surgery. Journal of Nuclear Medicine. 2025. doi:10.2967/jnumed.124.268151

BibTeX
@article{Schweiger2025,
  author = {Schweiger, Lilit and Maurer, Tobias and Simon, Ricarda and Horn, Thomas and Heck, Matthias and Weber, Wolfgang A and Eiber, Matthias and Rauscher, Isabel},
  title = {Pattern of Failure in Patients with Biochemical Recurrence After PSMA Radioguided Surgery},
  journal = {Journal of Nuclear Medicine},
  year = {2025},
  doi = {10.2967/jnumed.124.268151}
}
Kostenlos starten →